This study is currently not recruiting participants.

9785-CL-1121; A Phase 2 Multicenter Open-label Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With HER2+ AR+ Metastatic or Locally Advanced Breast Cancer

Study of Investigational Medications for Advanced Breast Cancer (Ages 18-65)

Not Recruiting
18 years - 100 years
Female
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to evaluate the efficacy of enzalutamide with trastuzumab in subjects with HER2+ AR+ and ER- metastatic or locally advanced breast cancer.

Detailed description of study

The purpose of this study is to evaluate the efficacy of enzalutamide with trastuzumab in subjects with HER2+ AR+ and ER- metastatic or locally advanced breast cancer.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Breast Cancer
  • Age: 18 years - 100 years
  • Gender: Female

This study investigates the effectiveness of a combination of investigational medications for individuals with HER2 positive, androgen receptor positive, and estrogen receptor negative metastatic or locally advanced breast cancer. HER2, AR, and ER are proteins found in some breast cancer cells, and their presence or absence can affect how the cancer grows and responds to treatment.

Participants in the study will receive a combination of investigational medications. The study will monitor the participants' response to the treatment, looking for changes in their cancer and any side effects they may experience.

  • Who can participate: The study is looking for participants aged 18-65 with HER2 positive, androgen receptor positive, and estrogen receptor negative metastatic or locally advanced breast cancer.
  • Study details: Participants will receive a combination of investigational medications as part of the study treatment. A placebo may be used, which is an inactive substance that looks like the investigational medicine but does not contain any medicine.
Updated on 19 Feb 2024. Study ID: 1406244848

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team